deferiprone has been researched along with Myelodysplastic Syndromes in 22 studies
Deferiprone: A pyridone derivative and iron chelator that is used in the treatment of IRON OVERLOAD in patients with THALASSEMIA.
deferiprone : A member of the class of 4-pyridones that is pyridin-4(1H)-one substituted at positions 1 and 2 by methyl groups and at position 3 by a hydroxy group. A lipid-soluble iron-chelator used for treatment of thalassaemia.
Myelodysplastic Syndromes: Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "One hundred thirteen patients with myelodysplastic syndromes (MDS) with <10% of bone marrow blasts received either deferiprone in a daily dose of 40-90 mg/kg (48 patients) or deferasirox in a daily dose of 10-40 mg/kg (65 patients)." | 7.79 | A comparative study of deferasirox and deferiprone in the treatment of iron overload in patients with myelodysplastic syndromes. ( Belohlavkova, P; Cermak, J; Cervinek, L; Jonasova, A; Neuwirtova, R; Vondrakova, J, 2013) |
| "Five, repeatedly transfused, patients with refractory anemia (RA) or RA with ringed sideroblast (RARS) subtypes of myelodysplastic syndrome (MDS), with serum ferritin (SF) levels of > 2,000 microg/L, and one female with Hb E [beta26(B8)Glu --> Lys]/beta0-thalassemia (thal) with an SF level of 1,760 microg/ L, were treated with deferiprone (L1) at the dose of 4-6 g per day for at least 26 months." | 5.12 | Erythropoietin administration may potentiate mobilization of storage iron in patients on oral iron chelation therapy. ( Cermák, J, 2006) |
| "One hundred thirteen patients with myelodysplastic syndromes (MDS) with <10% of bone marrow blasts received either deferiprone in a daily dose of 40-90 mg/kg (48 patients) or deferasirox in a daily dose of 10-40 mg/kg (65 patients)." | 3.79 | A comparative study of deferasirox and deferiprone in the treatment of iron overload in patients with myelodysplastic syndromes. ( Belohlavkova, P; Cermak, J; Cervinek, L; Jonasova, A; Neuwirtova, R; Vondrakova, J, 2013) |
| " Incidence of adverse effects was comparable to that in thalassemic patients." | 2.76 | Efficacy and safety of administration of oral iron chelator deferiprone in patients with early myelodysplastic syndrome. ( Cermak, J; Hochova, I; Jonasova, A; Neuwirtova, R; Siskova, M; Vondrakova, J; Walterova, L, 2011) |
| "Deferiprone was clearly not effective in three patients (two with myelofibrosis, one with myelodysplasia)." | 2.68 | Long-term treatment of transfusional iron overload with the oral iron chelator deferiprone (L1): a Dutch multicenter trial. ( Goudsmit, R; Kersten, MJ; Lameijer, W; Lange, R; Roozendaal, KJ; Smeets, ME; Vreugdenhil, G, 1996) |
| "Iron overload is characterized by excessive iron deposition and consequent injury and dysfunction of the heart, liver, anterior pituitary, pancreas, and joints." | 2.44 | Chelation therapy for iron overload. ( Barton, JC, 2007) |
| "Deferasirox is an oral iron-chelating agent with favorable pharmacokinetics, including a long half-life allowing continuous 24-hour chelation with once-daily dosing." | 2.44 | Novel treatment options for transfusional iron overload in patients with myelodysplastic syndromes. ( Goldberg, SL, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (22.73) | 18.2507 |
| 2000's | 7 (31.82) | 29.6817 |
| 2010's | 10 (45.45) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wong, SA | 1 |
| Leitch, HA | 1 |
| Ghosh, K | 2 |
| Cermak, J | 3 |
| Jonasova, A | 2 |
| Vondrakova, J | 2 |
| Cervinek, L | 1 |
| Belohlavkova, P | 1 |
| Neuwirtova, R | 2 |
| de Witte, T | 1 |
| Jang, JH | 1 |
| Lee, JH | 1 |
| Yoon, SS | 1 |
| Jo, DY | 1 |
| Kim, HJ | 1 |
| Chung, J | 1 |
| Lee, JW | 1 |
| Merkel, DG | 1 |
| Nagler, A | 1 |
| Malcovati, L | 1 |
| Fausel, CA | 1 |
| Walterova, L | 1 |
| Hochova, I | 1 |
| Siskova, M | 1 |
| Shah, J | 1 |
| Kurtin, SE | 1 |
| Arnold, L | 1 |
| Lindroos-Kolqvist, P | 1 |
| Tinsley, S | 1 |
| Ruivard, M | 1 |
| Greenberg, PL | 1 |
| Barton, JC | 1 |
| Ghoti, H | 1 |
| Amer, J | 1 |
| Winder, A | 1 |
| Rachmilewitz, E | 1 |
| Fibach, E | 1 |
| Goldberg, SL | 1 |
| Kontoghiorghes, GJ | 3 |
| Bartlett, AN | 3 |
| Sheppard, L | 2 |
| Barr, J | 2 |
| Nortey, P | 2 |
| Kersten, MJ | 1 |
| Lange, R | 1 |
| Smeets, ME | 1 |
| Vreugdenhil, G | 1 |
| Roozendaal, KJ | 1 |
| Lameijer, W | 1 |
| Goudsmit, R | 1 |
| Klinz, C | 1 |
| Rose, C | 1 |
| Cambier, N | 1 |
| Mahieu, M | 1 |
| Ernst, O | 1 |
| Fenaux, P | 1 |
| Hoffbrand, AV | 2 |
| Goddard, JG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effect of Treatment With the Oral Iron Chelator Deferiprone on the Oxidative Stress of Blood Cells and on Iron Overload Status in Transfusion Dependent, Iron-overloaded Patients With Low Risk Myelodysplastic Syndrome[NCT02477631] | Phase 2 | 19 participants (Actual) | Interventional | 2016-02-29 | Completed | ||
| A Trial of Oral Nifedipine for the Treatment of Iron Overload[NCT00712738] | Phase 1 | 6 participants (Actual) | Interventional | 2008-06-20 | Completed | ||
| Kinetics of the Plasmatic Concentration of L-Ascorbic Acid in Patient With Myelodysplastic Syndromes and Control Subjects[NCT02809222] | 138 participants (Actual) | Interventional | 2016-10-25 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 reviews available for deferiprone and Myelodysplastic Syndromes
| Article | Year |
|---|---|
Toward resolving the unsettled role of iron chelation therapy in myelodysplastic syndromes.
Topics: Administration, Oral; Benzoates; Blood Transfusion; Chelation Therapy; Deferasirox; Deferiprone; Def | 2014 |
Red blood cell transfusion therapy and iron chelation in patients with myelodysplastic syndromes.
Topics: beta-Thalassemia; Deferiprone; Disease Progression; DNA Methylation; Erythrocyte Transfusion; Erythr | 2009 |
Management of transfusion-related iron overload in patients with myelodysplastic syndromes.
Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating A | 2012 |
[Iron chelating therapy in adults: How and when ?].
Topics: Anemia, Sickle Cell; Benzoates; beta-Thalassemia; Deferasirox; Deferiprone; Deferoxamine; Humans; Ir | 2013 |
Myelodysplastic syndromes: iron overload consequences and current chelating therapies.
Topics: Administration, Oral; Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Erythroc | 2006 |
Chelation therapy for iron overload.
Topics: Anemia; Anemia, Sickle Cell; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferipron | 2007 |
Novel treatment options for transfusional iron overload in patients with myelodysplastic syndromes.
Topics: Benzoates; Deferasirox; Deferiprone; Drug-Related Side Effects and Adverse Reactions; Humans; Iron C | 2007 |
[Iron overload and myelodysplastic syndromes].
Topics: Administration, Oral; Aged; Biopsy; Chelation Therapy; Deferiprone; Deferoxamine; Erythrocyte Transf | 2001 |
6 trials available for deferiprone and Myelodysplastic Syndromes
| Article | Year |
|---|---|
Efficacy and safety of administration of oral iron chelator deferiprone in patients with early myelodysplastic syndrome.
Topics: Adult; Aged; Aged, 80 and over; Agranulocytosis; Deferiprone; Drug Therapy, Combination; Drug-Relate | 2011 |
Erythropoietin administration may potentiate mobilization of storage iron in patients on oral iron chelation therapy.
Topics: Administration, Oral; Anemia, Refractory; Deferiprone; Drug Administration Schedule; Drug Therapy, C | 2006 |
Oral iron chelation therapy with deferiprone. Monitoring of biochemical, drug and iron excretion changes.
Topics: Adult; Aged; Ascorbic Acid; beta-Thalassemia; Deferiprone; Feces; Female; Ferritins; Humans; Iron; I | 1995 |
Long-term treatment of transfusional iron overload with the oral iron chelator deferiprone (L1): a Dutch multicenter trial.
Topics: Adult; Aged; Aged, 80 and over; Agranulocytosis; Deferiprone; Female; Ferritins; Hemosiderosis; Huma | 1996 |
Long-term trial with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1). I. Iron chelation and metabolic studies.
Topics: Anemia; Blood Transfusion; Deferiprone; Ferritins; Half-Life; Humans; Iron; Iron Chelating Agents; M | 1990 |
Long-term trial with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1). II. Clinical observations.
Topics: Adolescent; Adult; Aged; Anemia; Blood Transfusion; Deferiprone; Female; Humans; Iron; Iron Chelatin | 1990 |
8 other studies available for deferiprone and Myelodysplastic Syndromes
| Article | Year |
|---|---|
Iron chelation therapy in lower IPSS risk myelodysplastic syndromes; which subtypes benefit?
Topics: Adult; Aged; Aged, 80 and over; Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine | 2018 |
Iron chelators or therapeutic modulators of iron overload: Are we anywhere near ideal one?
Topics: Animals; beta-Thalassemia; Chelating Agents; Deferiprone; Deferoxamine; Humans; Hydroxyurea; Iron Ov | 2018 |
A comparative study of deferasirox and deferiprone in the treatment of iron overload in patients with myelodysplastic syndromes.
Topics: Adult; Aged; Aged, 80 and over; Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Female; Ferr | 2013 |
Iron chelators in myelodysplastic syndrome: to lower ferritin levels or to improve survival?
Topics: Benzoates; Deferasirox; Deferiprone; Female; Humans; Iron Chelating Agents; Iron Overload; Male; Mye | 2013 |
Korean guideline for iron chelation therapy in transfusion-induced iron overload.
Topics: Anemia, Aplastic; Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Humans; Iron Chelating Age | 2013 |
Iron chelation therapy in myelodysplastic syndromes.
Topics: Benzoates; Cost-Benefit Analysis; Deferasirox; Deferiprone; Deferoxamine; Education, Continuing; Hum | 2010 |
Oxidative stress in red blood cells, platelets and polymorphonuclear leukocytes from patients with myelodysplastic syndrome.
Topics: Acetylcysteine; Aged; Aged, 80 and over; Antioxidants; Blood Platelets; Chelating Agents; Deferipron | 2007 |
Oxidative stress in red blood cells, platelets and polymorphonuclear leukocytes from patients with myelodysplastic syndrome.
Topics: Acetylcysteine; Aged; Aged, 80 and over; Antioxidants; Blood Platelets; Chelating Agents; Deferipron | 2007 |
Oxidative stress in red blood cells, platelets and polymorphonuclear leukocytes from patients with myelodysplastic syndrome.
Topics: Acetylcysteine; Aged; Aged, 80 and over; Antioxidants; Blood Platelets; Chelating Agents; Deferipron | 2007 |
Oxidative stress in red blood cells, platelets and polymorphonuclear leukocytes from patients with myelodysplastic syndrome.
Topics: Acetylcysteine; Aged; Aged, 80 and over; Antioxidants; Blood Platelets; Chelating Agents; Deferipron | 2007 |
[Marked hemosiderosis in myelodysplastic syndrome].
Topics: Aged; Deferiprone; Diabetes Mellitus, Type 2; Erythrocyte Transfusion; Heart Failure; Hemosiderosis; | 1999 |